A man with long‑term type 1 diabetes received an experimental treatment: insulin‑producing pancreatic islet cells from a donor. These cells were genetically modified—using CRISPR‑Cas12b and lentiviral methods—to make them “hypoimmune,” so the patient’s immune system would not reject them. They were transplanted into his forearm muscle, and he did not take any immunosuppressive drugs.
After 12 weeks:
Additionally, imaging studies (like PET‑MRI) confirmed that the cells survived at the transplant site and kept working stoculator.com+1.
This proof‑of‑concept study shows that it may be possible to transplant insulin‑producing cells without requiring lifelong immunosuppression—potentially a huge step toward a functional cure for type 1 diabetes nejm.org+10stoculator.com+10globenewswire.com+10.
Per-Ola Carlsson, et al. Survival of Transplanted Allogeneic Beta
Cells with No Immunosuppression NEJM.org 4.8. 2025
DOI: 10.1056/NEJMoa2503822
Der Antikörper richtet sich gegen das CD3-Protein auf T-Zellen, die fälschlicherweise die insulinproduzierenden Betazellen angreifen. Statt diese T‑Zellen zu eliminieren, versetzt Teplizumab sie in einen „exhausted“ (ermüdeten) Zustand, reduziert deren Angriffskraft und verlangsamt somit die Zerstörung der Betazellen. Dadurch verzögert sich der Beginn der insulinpflichtigen Phase (Stadium 3) um etwa zwei Jahre (sanofi.com).
Studienlage
Markteinführung: Wann ist der Markteintritt zu erwarten?
Deutschland / EU: Bis dato (Stand: 2025) ist TZIELD noch nicht zugelassen in Deutschland oder der EU (sanofi.com).
A comprehensive review from May 2024 emphasized the role of fat metabolism and adipogenic differentiation (bone marrow stem cells turning into fat cells instead of osteoblasts) in osteoporosis. Imbalances in lipid profiles promote inflammatory factors (e.g., IL‑1, IL‑6, TNF‑α), which in turn increase osteoclastic activity and bone resorption. Targeted modulation of lipid balance and reducing inflammation or oxidative stress may offer promising treatment strategies.
Wang X, Zhang C, Zhao G, Yang K and Tao L: Obesity and lipid metabolism in the development of osteoporosis (Review). Int J Mol Med 54: 61, 2024.
Abaloparatide is indicated to treat postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. Abaloparatide was approved for medical use in the United States in April 2017, and in the European Union in December 2022 nd is already available in the UK through the NHS. Abaloparatid (Tymlos / Eladynos is a parathyroid hormone-related protein (PTHrP) analogue medication used to treat osteoporosis. It is an anabolic (i.e., bone growing) agent.
A recent scoping review (published around May–June 2025) clearly shows that menopausal hormone therapy (MHT) combined with strength and impact training increases bone mineral density (BMD) more effectively than either intervention alone. Combined MHT (estrogen + progestin) is more beneficial than estrogen alone, especially when used long-term and at low doses.
It is concluded: „The management of osteoporosis during menopause requires a personalized and multi-faceted approach. While MHT and exercise independently support bone health, their combined use may offer synergistic benefits. Clinical decision-making should weigh individual risk profiles and current evidence to guide effective and safe interventions.“
Platt O, Bateman J and Bakour S (2025) Impact of menopause hormone therapy, exercise, and their combination on bone mineral density and mental wellbeing in menopausal women: a scoping review. Front. Reprod. Health 7:1542746. doi: 10.3389/frph.2025.1542746